Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Smith

Sports Medicine Naples, FL Medical Doctor

NPI 1639162225 CMS profile 73525

11190 Health Park Blvd Ste 2102, Naples, FL 34110

Open in the dashboard

General payments

$2,919,454

1,060 records reported · program years 2019–2025

Research payments

$91,150

Paid to them · 11 records reported · program years 2019–2025

Ownership & investment interest

$2,679,918

7 holdings reported · through program year 2025

Research they led as principal investigator

$303,891 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Patrick Smith of Naples, FL is reported in the CMS Open Payments database as having received $2,919,454 across 1,060 general payments and $91,150 in research payments paid to them. Separately, studies naming them as principal investigator received $303,891 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $2,679,918 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

17 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $834,402 149
2024 General $727,010 187
2024 Research $6,198 1
2023 General $449,536 166
2023 Research $17,367 3
2022 General $426,157 195
2022 Research $67,586 7
2021 General $142,665 143
2020 General $89,512 94
2019 General $250,171 126
2025 Ownership $505,376 1
2024 Ownership $505,376 1
2023 Ownership $434,197 1
2022 Ownership $434,197 1
2021 Ownership $338,104 1
2020 Ownership $231,334 1
2019 Ownership $231,334 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Smith
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Patrick Smith were reported at $834,402. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Patrick Smith Sports Medicine median Middle half National median
2019 $250,171 $1,176 $199–$4,249 $163
2020 $89,512 $708 $96–$2,890 $114
2021 $142,665 $1,213 $152–$3,994 $132
2022 $426,157 $1,230 $159–$3,998 $149
2023 $449,536 $584 $146–$2,836 $160
2024 $727,010 $628 $163–$3,168 $164
2025 $834,402 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $2,911,973 1,020 payments
  2. Kairos Surgical Inc $2,109 3 payments
  3. Medical Device Business Services, Inc. $1,403 2 payments
  4. Elite Orthopedics, LLC $1,317 3 payments
  5. United Orthopedics LLC $1,200 1 payment
  6. Breg, Inc $476 4 payments
  7. Fones Marketing Management, Inc. $222 2 payments
  8. Integra LifeSciences Corporation $147 1 payment
  9. Gemini Mountain Medical, LLC $119 1 payment
  10. Sanofi-Aventis U.S. LLC $63 2 payments
  11. Other $427 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $1,556,095 28 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $806,141 137 payments
  3. Consulting Fee $342,297 81 payments
  4. Travel and Lodging $195,671 307 payments
  5. Food and Beverage $15,892 502 payments
  6. Education $2,612 3 payments
  7. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $600 1 payment
  8. Long term medical supply or device loan $147 1 payment
Products named General payments · program years 2019–2025
  1. ARTHREX Knee & Hip - Implants - Suspensory Fixation - Tightrope II $988,550 11 payments
  2. ARTHREX Knee & Hip - Implants - Suspensory Fixation - Tightrope II $988,550 11 payments
  3. ARTHREX Knee & Hip - Implants - Suspensory Fixation - Tightrope II $988,550 11 payments
  4. ARTHREX Knee & Hip - Implants - Suspensory Fixation - Tightrope II $988,550 11 payments
  5. Arthrex Knee & Hip - Implants - Suspensory Fixation - TightRope II - BTB Implant Systems $516,469 4 payments
  6. Arthrex Knee & Hip - Implants - Suspensory Fixation - Quad Tendon ACL TRII - FTTR Implants with IB $516,469 4 payments
  7. Arthrex Knee & Hip - Implants - Suspensory Fixation - TightRope II - RT Implants with IB $516,469 4 payments
  8. Arthrex Knee & Hip - Implants - Suspensory Fixation - TightRope II - BTB Implants with IB $516,469 4 payments
  9. ARTHREX Knee & Hip - Instruments - Meniscal Repair - Scorpion $454,234 11 payments
  10. Arthrex Knee & Hip - Implants - ACL Repair - TightRope - Implants $386,162 3 payments
  11. Other $359,780 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Arthrex, Inc. $91,150 11 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Orthopedic Surgery: 203

Drug cost

$24

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 13 $24

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$81,691

Of which drugs: $22,646

Medicare patients

169

Average age 72

Services billed

3,987

81 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 59%
Diabetes 22%
Cancer 20%
Chronic kidney disease 18%
Ischemic heart disease 17%
Depression 14%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 35 3,120 $20,453
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 43 $33

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1,071 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record